Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Pfizer
Sasanlimab is an antibody that binds the inhibitory receptor PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2, which can restore natural killer cell and cytotoxic T-lymphocyte activity against tumor cells. It is being studied in non-muscle invasive bladder cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04165317 | Phase 3 | Non-muscle Invasive Bladder Cancer | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-muscle Invasive Bladder Cancer
Updated Nov 22, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →